T-cell Immunotherapy Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on T-cell Immunotherapy  Market 

5.1. COVID-19 Landscape: T-cell Immunotherapy  Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global T-cell Immunotherapy  Market, By Therapy Type

8.1. T-cell Immunotherapy  Market, by Therapy Type

8.1.1. CAR-T (Chimeric Antigen Receptor T cells)

8.1.1.1. Market Revenue and Forecast

8.1.2. TCR-engineered T cells

8.1.2.1. Market Revenue and Forecast

8.1.3. TILs (Tumor-Infiltrating Lymphocytes)

8.1.3.1. Market Revenue and Forecast

8.1.4. T-cell receptor mimic (TCRm) therapies

8.1.4.1. Market Revenue and Forecast

8.1.5. CAR-NK and CAR-Macrophage (adjacent/competing modalities

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global T-cell Immunotherapy  Market, By Engineering / Modification Technology

9.1. T-cell Immunotherapy  Market, by Engineering / Modification Technology

9.1.1. Viral vectors (lentivirus, retrovirus)

9.1.1.1. Market Revenue and Forecast

9.1.2. Non-viral methods (electroporation, transposons — e.g., Sleeping Beauty)

9.1.2.1. Market Revenue and Forecast

9.1.3. Gene editing (CRISPR/Cas, TALEN, ZFN)

9.1.3.1. Market Revenue and Forecast

9.1.4. mRNA / transient expression platforms

9.1.4.1. Market Revenue and Forecast

Chapter 10. Global T-cell Immunotherapy  Market, By Indication / Disease Area 

10.1. T-cell Immunotherapy  Market, by Indication / Disease Area

10.1.1. Malignancies

10.1.1.1. Market Revenue and Forecast

10.1.2. Solid tumors

10.1.2.1. Market Revenue and Forecast

Chapter 11. Global T-cell Immunotherapy  Market, By Vector / Targeting Strategy

11.1. T-cell Immunotherapy  Market, by Vector / Targeting Strategy

11.1.1. Single-antigen targeting (e.g., CD19, BCMA)

11.1.1.1. Market Revenue and Forecast

11.1.2. Dual/multi-antigen targeting

11.1.2.1. Market Revenue and Forecast

11.1.3. Logic-gated CARs (AND, OR, NOT)

11.1.3.1. Market Revenue and Forecast

11.1.4. Affinity-tuned / safety-switched CARs (suicide switches)

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global T-cell Immunotherapy  Market, By End User / Care Setting

12.1. T-cell Immunotherapy  Market, by End User / Care Setting

12.1.1. Hospitals (tertiary/academic cancer centers)

12.1.1.1. Market Revenue and Forecast

12.1.2. Specialty cell therapy centers / infusion centers

12.1.2.1. Market Revenue and Forecast

12.1.3. Ambulatory surgical centers (emerging)

12.1.3.1. Market Revenue and Forecast

12.1.4. Research / clinical trial sites

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global T-cell Immunotherapy  Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Therapy Type

13.1.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.1.3. Market Revenue and Forecast, by Indication / Disease Area

13.1.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.1.5. Market Revenue and Forecast, by End User / Care Setting

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Therapy Type

13.1.6.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.1.6.3. Market Revenue and Forecast, by Indication / Disease Area

13.1.6.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.1.6.5. Market Revenue and Forecast, by End User / Care Setting  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Therapy Type

13.1.7.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.1.7.3. Market Revenue and Forecast, by Indication / Disease Area

13.1.7.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.1.7.5. Market Revenue and Forecast, by End User / Care Setting

13.2. Europe

13.2.1. Market Revenue and Forecast, by Therapy Type

13.2.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.2.3. Market Revenue and Forecast, by Indication / Disease Area

13.2.4. Market Revenue and Forecast, by Vector / Targeting Strategy  

13.2.5. Market Revenue and Forecast, by End User / Care Setting  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Therapy Type

13.2.6.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.2.6.3. Market Revenue and Forecast, by Indication / Disease Area

13.2.7. Market Revenue and Forecast, by Vector / Targeting Strategy  

13.2.8. Market Revenue and Forecast, by End User / Care Setting  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Therapy Type

13.2.9.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.2.9.3. Market Revenue and Forecast, by Indication / Disease Area

13.2.10. Market Revenue and Forecast, by Vector / Targeting Strategy

13.2.11. Market Revenue and Forecast, by End User / Care Setting

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Therapy Type

13.2.12.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.2.12.3. Market Revenue and Forecast, by Indication / Disease Area

13.2.12.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.2.13. Market Revenue and Forecast, by End User / Care Setting

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Therapy Type

13.2.14.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.2.14.3. Market Revenue and Forecast, by Indication / Disease Area

13.2.14.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.2.15. Market Revenue and Forecast, by End User / Care Setting

13.3. APAC

13.3.1. Market Revenue and Forecast, by Therapy Type

13.3.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.3.3. Market Revenue and Forecast, by Indication / Disease Area

13.3.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.3.5. Market Revenue and Forecast, by End User / Care Setting

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Therapy Type

13.3.6.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.3.6.3. Market Revenue and Forecast, by Indication / Disease Area

13.3.6.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.3.7. Market Revenue and Forecast, by End User / Care Setting

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Therapy Type

13.3.8.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.3.8.3. Market Revenue and Forecast, by Indication / Disease Area

13.3.8.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.3.9. Market Revenue and Forecast, by End User / Care Setting

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Therapy Type

13.3.10.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.3.10.3. Market Revenue and Forecast, by Indication / Disease Area

13.3.10.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.3.10.5. Market Revenue and Forecast, by End User / Care Setting

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Therapy Type

13.3.11.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.3.11.3. Market Revenue and Forecast, by Indication / Disease Area

13.3.11.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.3.11.5. Market Revenue and Forecast, by End User / Care Setting

13.4. MEA

13.4.1. Market Revenue and Forecast, by Therapy Type

13.4.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.4.3. Market Revenue and Forecast, by Indication / Disease Area

13.4.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.4.5. Market Revenue and Forecast, by End User / Care Setting

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Therapy Type

13.4.6.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.4.6.3. Market Revenue and Forecast, by Indication / Disease Area

13.4.6.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.4.7. Market Revenue and Forecast, by End User / Care Setting

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Therapy Type

13.4.8.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.4.8.3. Market Revenue and Forecast, by Indication / Disease Area

13.4.8.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.4.9. Market Revenue and Forecast, by End User / Care Setting

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Therapy Type

13.4.10.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.4.10.3. Market Revenue and Forecast, by Indication / Disease Area

13.4.10.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.4.10.5. Market Revenue and Forecast, by End User / Care Setting

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Therapy Type

13.4.11.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.4.11.3. Market Revenue and Forecast, by Indication / Disease Area

13.4.11.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.4.11.5. Market Revenue and Forecast, by End User / Care Setting

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Therapy Type

13.5.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.5.3. Market Revenue and Forecast, by Indication / Disease Area

13.5.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.5.5. Market Revenue and Forecast, by End User / Care Setting

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Therapy Type

13.5.6.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.5.6.3. Market Revenue and Forecast, by Indication / Disease Area

13.5.6.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.5.7. Market Revenue and Forecast, by End User / Care Setting

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Therapy Type

13.5.8.2. Market Revenue and Forecast, by Engineering / Modification Technology

13.5.8.3. Market Revenue and Forecast, by Indication / Disease Area

13.5.8.4. Market Revenue and Forecast, by Vector / Targeting Strategy

13.5.8.5. Market Revenue and Forecast, by End User / Care Setting

Chapter 14. Company Profiles

14.1. Adaptimmune Therapeutics

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Allogene Therapeutics

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Cellectis

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Takara Bio

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Unum Therapeutics

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Poseida Therapeutics

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Gracell Biotechnologies

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. EsoBiotec

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Innovative Cellular Therapeutics

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Sinobioway Cell Therapy

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms